JIN 001
Alternative Names: JIN-001; MPT0B64; MPT0B640Latest Information Update: 09 May 2025
At a glance
- Originator Joseah Biopharma
- Developer J Ints Bio; University of Texas M. D. Anderson Cancer Center
- Class Amides; Antineoplastics; Antivirals; Aromatic hydrocarbons; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Glioblastoma; Ovarian cancer; Parkinson's disease
- Discontinued COVID 2019 infections
Most Recent Events
- 30 Apr 2025 J INTS BIO plans a clinical trials for Ovarian cancer (Second-line therapy or greater)
- 28 Apr 2025 No recent reports of development identified for preclinical development in Glioblastoma(Combination therapy) in USA
- 28 Apr 2025 No recent reports of development identified for preclinical development in Glioblastoma(Monotherapy) in USA